Literature DB >> 9690720

Dose-response relationship of lansoprazole to gastric acid antisecretory effects.

R A Blum1, R H Hunt, S L Kidd, H Shi, D E Jennings, P A Greski-Rose.   

Abstract

BACKGROUND: Proton pump inhibitors have been found to be effective in numerous studies in patients with peptic ulcer disease, particularly associated with Helicobacter pylori and gastro-oesophogeal reflux disorders. Optimal healing rates of antisecretory therapy for peptic acid disease is dependent upon the degree and duration of acid suppression and the length of treatment.
OBJECTIVE: To evaluate the extent and duration of gastric acid suppression of several lansoprazole regimens, administered for 5 consecutive days in 32 healthy adult male subjects.
METHODS: Intragastric 24-h pH monitoring was performed in 32 healthy subjects in a randomized, double-blind, four-way crossover study. Sixteen subjects (Group 1) received lansoprazole 30 mg o.d. (once daily), 15 mg b.d. (twice daily), 30 mg b.d. and 30 mg t.d.s. (three times a day) for 5 days; and 16 subjects (Group 2) received lansoprazole 30 mg o.d., 60 mg o.d., 60 mg b.d. and 60 mg t.d.s. for 5 days.
RESULTS: Mean 24-h intragastric pH values for lansoprazole 30 mg o.d., 15 mg b.d., 30 mg b.d. and 30 mg t.d.s. were 4.47, 4.57, 5.07 and 5.63, respectively. Multiple-dose regimens of lansoprazole 30 mg b.d. and t.d.s. produced greater acid suppression compared to lansoprazole 30 mg o.d. and 15 mg b.d. There was no significant difference in acid suppression between lansoprazole 30 mg o.d. and 15 mg b.d. Mean 24-h intragastric pH values for lansoprazole 30 mg o.d., 60 mg o.d., 60 mg b.d. and 60 mg t.d.s. were 4.13, 4.45, 5.19 and 5.13, respectively. Multiple-dose regimens of lansoprazole 60 mg b.d. and t.d.s. produced significantly greater acid suppression compared to lansoprazole 30 mg o.d. and 60 mg o.d. There was no significant difference in acid suppression between lansoprazole 30 mg o.d. and 60 mg o.d. Lansoprazole 30 mg t.d.s., 60 mg b.d. and 60 mg t.d.s. produced significantly greater percentage time above pH 3, 4, 5 and 6 than did lansoprazole 30 mg o.d. Post-regimen serum gastrin values increased by 50-130% from pre-study mean values but remained within normal range and returned to pre-study values 7-14 days post-dosing.
CONCLUSIONS: Multiple-dose regimens of lansoprazole (> or =30 mg b.d. for 5 days) produce significantly increased intragastric pH and significantly longer duration of increased intragastric pH than does lansoprazole 30 mg administered once daily.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9690720     DOI: 10.1046/j.1365-2036.1998.00306.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  8 in total

1.  Acid-independent gastroprotective effects of lansoprazole in experimental mucosal injury.

Authors:  C Blandizzi; G Natale; G Gherardi; G Lazzeri; C Marveggio; R Colucci; D Carignani; M Del Tacca
Journal:  Dig Dis Sci       Date:  1999-10       Impact factor: 3.199

2.  A clinical study to examine the potential effect of lansoprazole on the pharmacokinetics of bosutinib when administered concomitantly to healthy subjects.

Authors:  Richat Abbas; Cathie Leister; Daryl Sonnichsen
Journal:  Clin Drug Investig       Date:  2013-08       Impact factor: 2.859

3.  Effectiveness of three times daily lansoprazole/amoxicillin dual therapy for Helicobacter pylori infection in Korea.

Authors:  Seung Young Kim; Sung Woo Jung; Jeong Han Kim; Ja Seol Koo; Hyung Joon Yim; Jong Jae Park; Hoon Jai Chun; Sang Woo Lee; Jai Hyun Choi
Journal:  Br J Clin Pharmacol       Date:  2012-01       Impact factor: 4.335

4.  A Review of Nutrients and Compounds, Which Promote or Inhibit Intestinal Iron Absorption: Making a Platform for Dietary Measures That Can Reduce Iron Uptake in Patients with Genetic Haemochromatosis.

Authors:  Nils Thorm Milman
Journal:  J Nutr Metab       Date:  2020-09-14

Review 5.  The use of proton pump inhibitors in children: a comprehensive review.

Authors:  Troy E Gibbons; Benjamin D Gold
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

Review 6.  Diagnostic and therapeutic options in the management of nonvariceal upper gastrointestinal bleeding.

Authors:  Shireen Andrade Pais; Russell Yang
Journal:  Curr Gastroenterol Rep       Date:  2003-12

Review 7.  Relative potency of proton-pump inhibitors-comparison of effects on intragastric pH.

Authors:  Julia Kirchheiner; Silke Glatt; Uwe Fuhr; Ulrich Klotz; Ingolf Meineke; Thomas Seufferlein; Jürgen Brockmöller
Journal:  Eur J Clin Pharmacol       Date:  2008-10-17       Impact factor: 2.953

8.  Antiresorptive effect of a cathepsin K inhibitor ONO-5334 and its relationship to BMD increase in a phase II trial for postmenopausal osteoporosis.

Authors:  Makoto Tanaka; Yoshitaka Hashimoto; Chihiro Hasegawa; Steve Deacon; Richard Eastell
Journal:  BMC Musculoskelet Disord       Date:  2017-06-19       Impact factor: 2.362

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.